Nasdaq Introduces Counterparty Clearing for Small and Medium Enterprises in Europe
Strong market support for solution aiming at mitigating counterparty risk and potentially add liquidity to Nasdaq Stockholm Small Cap and Nasdaq First North
STOCKHOLM, Sweden, June 03, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the introduction of a central counterparty (CCP) participant for equity trading on Nasdaq First North in the Nordics, and Nasdaq Stockholm Small Cap*. This change will mitigate counterparty risk when trading in shares of small- and medium sized companies, while improving market efficiency and potentially increasing liquidity.
Starting today, trading on Nasdaq First North and Nasdaq Stockholm Small Cap will now have the same post-trade process as the Mid and Large Cap segments. The introduction of CCP Clearing will also increase access to Nasdaq First North and Nasdaq Stockholm Small Cap to institutional investors requiring central counterparties in order to make investments.
“With Nasdaq First North, one of Europe’s leading capital raising markets for growth companies, and also our Main Market Small Cap segments in Stockholm, Copenhagen and Helsinki, Nasdaq provides some of Europe’s most attractive markets for small and medium sized enterprises,” says Lauri Rosendahl, President, Nasdaq Stockholm. “We have been working together with market members, security dealer associations and investors across the region as well as our interoperable CCPs in order to ensure a smooth and market friendly transition.”
By introducing a central counterparty, counterparty risk is redistributed from the two parties involved in the trade, to a central counterparty participant – a third party firm specialized in managing risk. By removing bilateral risk, Nasdaq aims to attract more liquidity and thereby improve price formation.
“We fully support Nasdaq’s efforts to reduce the risk and potentially increase the liquidity pool in small- and medium sized companies,” says Patrik Tigerschiöld, Chairman of Bure Equity AB. “We are also happy to see that trading conditions between Nasdaq’s European markets have been further aligned, increasing overall market efficiency.”
The introduction of counterparty clearing on Nasdaq First North and Stockholm Small Cap is the final step of a transformation to central counterparty clearing for all shares listed on Nasdaq’s equity markets in Sweden, Denmark and Finland.
* Companies listed on Nasdaq European Markets belong to a market cap segment (Small-, Mid- and Large Cap) based on their average market value during the given review month. The market cap calculations are based on the total number of shares, i.e. both listed and non-listed shares, of a company. Companies with a market value exceeding EUR 1 billion are in the group of “Large Cap”. Companies with a market value between EUR 150 million and EUR 1 billion belong to the “Mid Cap” segment, while companies with a market value smaller than EUR 150 million belong to “Small Cap”.
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to over 4,000 total listings with a market value of approximately $14 trillion.
To learn more, visit business.nasdaq.com
Media relations contact:
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor20.8.2019 17:45:00 CEST | Press release
Inventiva secures new patent in the US strengthening the protection of its lead product candidate lanifibranor New patent granted in the United States by the USPTO protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035 This patent strengthens the protection of lanifibranor in the United States Daix (France), August 20, 2019 – Inventiva (Euronext: IVA), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of diseases in the areas of fibrosis, lysosomal storage disorders and oncology, today announced that the United States Patent and Trademark Office (USPTO) granted a new patent on August 20, 2019 that protects the use of lanifibranor for the treatment of fibrotic diseases until June 2035. This new patent further strenghens Inventiva’s patent portfolio for lanifibranor, the Company’s lead product candidate, in the United States, which already comprised a New Chemical Entity (NCE) patent and a patent protect
Banks net position in the Riksbank20.8.2019 16:44:00 CEST | Press release
AUG 20, 2019 SEK MILLION LENDING BORROWING 301
Permission issued to increase the authorised capital of AB Klaipedos nafta subsidiary UAB SGD terminalas20.8.2019 16:00:00 CEST | Press release
With the permission of the Ministry of Finance of the Republic of Lithuania, obtained by AB Klaipedos nafta (hereinafter - the Company), came into force the Company’s board decision to increase the authorised capital of the Company’s subsidiary UAB SGD terminalas in the amount of EUR 10 000. Jonas Lenkšas, Chief Financial Officer, +370 694 80594
PCI Biotech: Invitation to second quarter and first half 2019 results presentation20.8.2019 15:38:00 CEST | Press release
Oslo, Norway, 20 August 2019 - PCI Biotech invites to a presentation of the company's second quarter and first half 2019 results on Wednesday 28 August 2019 at Oslo Cancer Cluster Innovation Park. Time: Wednesday 28 August, 08:30am – 09:30am CEST (local time). Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo. The presentation will be held in English and if you wish to attend the presentation, please confirm with an e-mail to firstname.lastname@example.org. The presentation will also be a live webcast and can be accessed through www.pcibiotech.com. It will be possible to post questions through the webcast console. The interim report and the presentation will be available on www.newsweb.no and on the company's webpage, www.pcibiotech.com from 07:00am (CEST) on 28 August 2019. For further information, please contact: Ronny Skuggedal, CFO Email: email@example.com Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutica
Regarding resignation of member of the Supervisory Board20.8.2019 15:30:00 CEST | Press release
We hereby inform that, T. Lukoševičius, a member of Supervisory Board of AB Klaipedos nafta (hereinafter – the Company) 20 August 2019 submitted a notice of resignation of members of Supervisory Board of the Company as of 3 September 2019 (this day is the last day of the mandate). It should be noted that, currently the Supervisory Board of the Company consists of 3 members, 2 of them are independent. After the resignation of T. Lukoševičius, the Ministry of Energy of the Republic of Lithuania will conduct the selection of new member of the Supervisory Board. The Supervisory Board is elected by the General Meeting of Shareholders for 4 years. If individual members of the Supervisory Board are elected, they shall be elected only until the end of the term of office of the current Supervisory Board. Jonas Lenkšas, Chief Financial Officer,+370 694 80594
SERSTECH AB: Boardmember Anna Werntoft resigns from the Board of Serstech20.8.2019 13:40:00 CEST | Press release
Anna Werntoft will leave the board of directors effective on the 30th of September. The reason for her resignation is that she enters a new operational position with terms that does not allow external assignments. Serstech wishes Anna all the best in her new position and would like to thank her for her contribution while being on the Serstech Board. The Serstech will consist of three Board members until the vacant position is filled. The search for a replacement has started and will be concluded before the next annual general meeting. For further information, please contact: Stefan Sandor, CEO, Serstech AB tel: +46 739 606067 email: firstname.lastname@example.org Thomas Pileby, Chairman of the Board, Serstech AB tel: +46 702 072643 email: email@example.com Company website: www.serstech.com The information was submitted for publication, through the agency of the contact person set out above at 13:40 CET on August 20, 2019. Certified advisor to Serstech is Västra Hamnen Corporate Finance AB, phone: 040-2